---
title: "Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target Reaffirmed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285188212.md"
description: "Analyst Douglas Tsao of H.C. Wainwright has maintained a Buy rating on Evolus, reaffirming a price target of $13.00. This decision is based on Evolus' strong first-quarter performance, positive adjusted EBITDA, and guidance for double-digit revenue growth. Tsao highlights the company's effective commercial strategy and stable market share, indicating resilience amid macro pressures. Mizuho Securities also reiterated a Buy rating with a $15.00 price target."
datetime: "2026-05-05T10:35:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285188212.md)
  - [en](https://longbridge.com/en/news/285188212.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285188212.md)
---

# Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target Reaffirmed

Analyst Douglas Tsao of H.C. Wainwright maintained a Buy rating on Evolus, retaining the price target of $13.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Douglas Tsao has given his Buy rating due to a combination of factors, including Evolus’ solid first-quarter performance and confirmation of its 2026 outlook. The company modestly exceeded Street revenue expectations, sustained positive adjusted EBITDA for a second straight quarter, and reiterated guidance for double-digit revenue growth with improving margins, signaling an increasingly scalable business model.

Tsao also views Evolus’ commercial strategy as well suited to a value-focused consumer backdrop, as the company emphasizes perceived value through loyalty programs and partnerships rather than aggressive discounting. Stable U.S. toxin market share, high account penetration, and rising loyalty membership indicate resilient engagement, supporting confidence that Evolus can navigate macro pressures and achieve its growth and profitability targets, which underpins the unchanged $13 price target and Buy rating.

In another report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $15.00 price target.

### Related Stocks

- [EOLS.US](https://longbridge.com/en/quote/EOLS.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)